MRI Hippocampus Differential Response to Donepezil vs Placebo in Mild Cognitive Impairment and Alzheimer’s Disease: A Systematic Review of Four Randomized Clinical Trials
Youssef A. Ismail, Youssef Haitham, Mohammad Walid, Hazim Mohamed, Youssef M. Abd El‐Satar · 2025
Read MRI Hippocampus Differential Response to Donepezil vs Placebo in Mild Cognitive Impairment and Alzheimer’s Disease: A Systematic Review of Four Randomized Clinical Trials by Youssef A. Ismail, Youssef Haitham, Mohammad Walid, Hazim Mohamed, Youssef M. Abd El‐Satar (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11713534.txt.
Description
Youssef Ismail and co-authors review four clinical trials of the drug donepezil in this 2025 paper. Donepezil is a standard drug for Alzheimer's disease and mild memory impairment. The authors ask whether the drug slows shrinking of the hippocampus, a brain area key to memory.
The team searched major medical databases and kept only trials that compared the drug with a placebo using brain scans. Four trials qualified, with five hundred ninety-nine people in total, followed for twelve months. The review weighs whether scan results show a real edge for the drug. Such evidence helps doctors judge what the medicine can and cannot do.
Catalog record
| CREATOR | Youssef A. Ismail, Youssef Haitham, Mohammad Walid, Hazim Mohamed, Youssef M. Abd El‐Satar |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |